iNtRON Biotechnology ("iNtRON", www.intodeworld.com) has unveiled a groundbreaking development in cancer treatment with the announcement of PHAGERIA®, a potent anti-cancer candidate with broad antimicrobial activity against Enterotoxigenic B. fragilis (ETBF), a microbe associated with colorectal cancer..

Through in-vitro Evolution technology, iNtRON induced the evolution of specific genes of ETBF bacteriophages under specialized experimental conditions, resulting in the selection of PHAGERIA® anti-cancer candidates with enhanced antimicrobial activity. This breakthrough marks the first application of in-vitro Evolution technology to ETBF bacteriophages, underscoring the excellence of iNtRON's bacteriophage gene editing and robotic improvement platform.

Dr. SON, Ji-soo, Head of the BD Department, highlighted the significance of targeting ETBF: "As ETBF is known to have a direct correlation with colorectal cancer, it was the primary focus of our screening for PHAGERIA® anti-cancer candidates." He expressed plans to expand the technology's application to other bacteriophages, aiming to enhance broad antimicrobial properties against harmful gut microbiomes.

Mr. YOON, Kyung-won, CEO of iNtRON, emphasized the company's commitment to bacteriophage-based drug development: "The Robotic Bacteriophage Improvement Platform technology is the cornerstone of our endeavors, enabling the development of not only PHAGERIA®, but also PHAGERUS® for antiviral agents and PHAGERIARUS® for immune-modulating agents." He pledged continued investment in research and development to solidify iNtRON's position as a global leader in bacteriophage technology.

iNtRON's groundbreaking work with PHAGERIA® signifies a significant step forward in the fight against colorectal cancer, offering hope for improved treatment outcomes through innovative biotechnological solutions.